MBRX CEO Walter Klemp Sells Shares Amidst Insider Trading Activity
Walter Klemp, CEO and President of MBRX, sold 360 shares on June 22, 2026.
Key Points
- Walter Klemp, CEO of MBRX, sold 360 shares on June 22, 2026, with no disclosed value.
- MBRX shares traded at $2.93 on Thursday, with significant insider and institutional activity noted.
- Analysts from HC Wainwright & Co. reiterated a buy rating with a $22 target on March 24, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Walter Klemp, CEO and President of MBRX, sold 360 shares of the company on June 22, 2026. The transaction didn't disclose a value. This move comes as part of a series of insider trading activities within the company.
Insider Buying and Selling at Moleculin Biotech, Inc.
On June 22, 2026, several insiders engaged in trading activities at MBRX. Walter Klemp, the CEO and President, sold 360 shares without a disclosed price or value. Additionally, Jonathan Foster, the Chief Financial Officer, sold 41 shares at $3.12 each and purchased 174 shares. Donald Picker, the Chief Science Officer, also traded shares, buying 71 shares and selling 21 shares at $3.12 each.
Other Institutional Activity in MBRX
Several institutional investors have shown interest in MBRX. Sabby Management, LLC opened a new position with 75,021 shares valued at about $171,798. Geode Capital Management, LLC increased its holdings by 17,191 shares, resulting in 32,329 shares worth approximately $74,033, marking a 113.6% increase. Rockefeller Capital Management L.P. significantly boosted its stake by 4,203 shares, reaching 4,421 shares valued at $10,124, a 1,928% increase.
Moleculin Biotech, Inc. Stock Up 350.8%
Shares of MBRX traded around $2.93 on Thursday. The stock has seen various institutional activities and insider transactions recently. However, specific metrics like market cap, P/E ratio, or beta were not available at this time.
$MBRX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On March 24, 2026, HC Wainwright & Co. reiterated its buy rating for MBRX with a price target of $22. Previously, on December 11, 2025, the firm maintained its buy rating with the same target. The consensus among analysts remains positive, with multiple firms holding a buy rating on the stock.
Bottom Line
Walter Klemp's sale of shares is part of broader insider trading activity at MBRX. Investors often watch such moves to gauge insider sentiment, but these transactions do not necessarily indicate the company's future performance. Institutional interest and analyst ratings suggest continued attention on MBRX, though it's important to remember that insider trades are disclosed after the fact and may not reflect current positions.
Get Moleculin Biotech, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MBRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.